P. Ibrahim

发表

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

S. Kerwar, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Vemurafenib: the first drug approved for BRAF-mutant cancer

P. Hirth, K. Nolop, G. Bollag, 2012, Nature Reviews Drug Discovery.

Phosphodiesterase-4 as a potential drug target

Kam Y. J. Zhang, G. Bollag, P. Ibrahim, 2005, Expert opinion on therapeutic targets.

Structural basis for the activity of drugs that inhibit phosphodiesterases.

Kam Y. J. Zhang, Sung-Hou Kim, M. Milburn, 2004, Structure.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

Kam Y. J. Zhang, Chao Zhang, Kam Y J Zhang, 2005, Nature Biotechnology.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Kam Y. J. Zhang, James Tsai, Nikolas K. Haass, 2008, Proceedings of the National Academy of Sciences.

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Kam Y. J. Zhang, G. Habets, P. Hirth, 2013, Proceedings of the National Academy of Sciences.

Methyl transfers. 15. CoIPc- as a nucleophile and leaving group

P. Ibrahim, W. Gałęzowski, E. Lewis, 1993 .

Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice

G. Bollag, P. Ibrahim, E. Saiah, 2010, Diabetes, obesity & metabolism.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Lindsey T. Brinton, J. Byrd, G. Habets, 2018, Cancer discovery.

Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF).

Zhihe Li, P. Ibrahim, Hiba Ahmed, 2004, Bioorganic & medicinal chemistry letters.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

S. Kerwar, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.

David A. Lustig, S. Kerwar, Xiaofen Li, 2004, Bioorganic & medicinal chemistry letters.

Conditional-dependent effects of CVT-4325, a novel fatty acid oxidation inhibitor, on palmitate utilization

L. Belardinelli, P. Ibrahim, B. Blackburn, 2003 .

Photolysis of nitro-β,γ alkenes: nitro-2,5-cyclohexadienes

P. Ibrahim, A. Fischer, 1990 .

An efficient one-pot construction of substituted pyrimidinones

C. Dominguez, M. Bartberger, P. Ibrahim, 2006 .

Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

J. Grippo, P. Ibrahim, D. Choi, 2013, Journal of pharmaceutical sciences.

Combinatorial synthesis of SSAO inhibitors using sonogashira coupling: SAR of aryl propargylic amines.

P. Ibrahim, R. Shimmon, C. Conn, 2001, Bioorganic & medicinal chemistry letters.

RAF inhibitors that evade paradoxical MAPK pathway activation

James Tsai, Ying Zhang, Paul S. Lin, 2015, Nature.

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

A. Kasarskis, R. Sebra, A. Bashir, 2015, Cancer discovery.

Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.

Yoshihisa Suzuki, V. Mandiyan, J. Tsai, 2005, Journal of molecular biology.

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Chao Zhang, Ying Zhang, Wayne Spevak, 2019, Nature Communications.

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Shenghua Shi, Kam Y. J. Zhang, Sarah Will, 2009, Proceedings of the National Academy of Sciences.

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents.

David A. Lustig, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.

A. Shields, W. Tap, G. Habets, 2021, JAMA oncology.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Preclinical development of a novel inhibitor of oncogenic B-Raf.

P. Hirth, K. Nolop, G. Bollag, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-range spin density propagation in saturated hydrocarbons: 3-[n]staffyl radicals

J. Michl, A. McKinley, P. Ibrahim, 1992 .